Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects

British Journal of Clinical Pharmacology

Volumn 78, Issue 5, 2014, Pages 1122-1134

  Kasichayanula, Sreeneeranj ^a   Boulton, David W ^a   Luo, Wen Lin ^a   Rodrigues, A David ^a   Yang, Zheng ^a   Goodenough, Angela ^a   Lee, Michelle ^a   Jemal, Mohammed ^a   LaCreta, Frank ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

4 hydroxycholesterol; Biomarkers; CYP3A; Drugdrug interactions; Midazolam; Saliva

Indexed keywords

BIOLOGICAL MARKER; CHOLEST-5-ENE-3,4-DIOL; CHOLESTEROL DERIVATIVE; CYP3A PROTEIN, HUMAN; CYTOCHROME P450 3A; CYTOCHROME P450 3A INDUCER; CYTOCHROME P450 3A INHIBITOR; KETOCONAZOLE; MIDAZOLAM; RIFAMPICIN;

ADOLESCENT; ADULT; BLOOD; CHEMISTRY; CLINICAL TRIAL; DOSE RESPONSE; ENZYME SPECIFICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIMIT OF DETECTION; METABOLISM; MIDDLE AGED; NORMAL HUMAN; SALIVA; TIME; TISSUE DISTRIBUTION; VALIDATION STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INDUCERS; CYTOCHROME P-450 CYP3A INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTHY VOLUNTEERS; HUMANS; HYDROXYCHOLESTEROLS; INJECTIONS, INTRAVENOUS; KETOCONAZOLE; LIMIT OF DETECTION; MIDAZOLAM; MIDDLE AGED; RIFAMPIN; SALIVA; SUBSTRATE SPECIFICITY; TIME FACTORS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84918810467     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12425     Document Type: Article

References (28)

1. United States Food and Drug Administration. Guidance for Industry Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, February 2012.
2. European Medicines Agency. Guideline on the Investigation of Drug Interactions CPMP/EWP/560/95/Rev. 1, 2012.
3. Lund E, Diczfalusy U, Björkhem I. On the mechanism of oxidation of cholesterol at C-7 in a lipoxygenase system. J Biol Chem 1992; 267: 12462-7.
4. Breuer O. Identification and quantitation of cholest-5-ene-3?,4? diol in rat liver and human plasma. J Lipid Res 1995; 36: 2275-81.
5. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57.
6. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P. The increase in urinary excretion of 6 -hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J ClinPharmacol 1989; 28: 373-87.
7. Peng CC, Templeton I, Thummel KE, Davis C, Kunze KL, Isoherranen N. Evaluation of 6-hydroxycortisol, 6-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2011; 89: 888-95.
8. Diczfalusy U, Miura J, Roh H-K, Mirghani RA, Sayi J, Larsson H, Bodin KG, Allqvist A, Jande M, Kim J-W, Aklillu E, Gustafsson LL, Bertilsson L. 4b-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 2008; 18: 201-8.
9. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broomé U, Einarsson C, Diczfalusy U. Antiepileptic drugs increase plasma levels of 4-hydroxycholesterol in humans. J Biol Chem 2001; 276: 38685-9.
10. Goodenough AK, Onorato JM, Ouyang Z, Chang S, Rodrigues AD, Kasichayanula S, Huang SP, Turley W, Burrell R, Bifano M, Jemal M, LaCreta F, Tymiak A, Wang-Iverson D. Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. Chem Res Toxicol 2011; 19: 1575-85.
11. Yang Z, Rodrigues AD. Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric J Clin Pharmacol 2010; 50: 1330-8.
12. Diczfalusy U, Nylén H, Elander P, Bertilsson L. 4-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol 2011; 71: 183-9.
13. Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, Bertilsson L. 4-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity: stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol 2009; 67: 38-43.
14. Bodin K, Andersson U, Rystedt E, Ellis E, Norlin M, Pikuleva I, Eggertsen G, Björkhem I, Diczfalusy U. Metabolism of 4-hydroxycholesterol in humans. J Biol Chem 2002; 277: 31534-40.
15. Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Hand Exp Pharmacol. 2008; 182: 335-60.
16. Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg Med 1997; 15: 357-65.
17. Link B, Haschke M, Grignaschi N, Bodmer M, Aschmann YZ, Wenk M, Krähenbühl S. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br J Clin Pharmacol 2008; 66: 473-84.
18. Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA. An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 2004; 32: 140-8.
19. Tomalik-Scharte D, Lütjohann D, Doroshyenko O, Frank D, Jetter A, Fuhr U. Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric Clin Pharmacol Ther 2009; 86: 147-53.
20. FDA. FDA Draft Guidance for Industry Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, February 2012.
21. Lütjohann D, Marinova M, Schneider B, Oldenburg J, von Bergmann K, Bieber T, Björkhem I, Diczfalusy U. 4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo-effects of itraconazole in man. Int J Clin Pharmacol Ther 2009; 47: 7097-115.
22. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999; 66: 461-71.
23. Gylling H, Vanhanen H, Miettinen TA. Effects of ketoconazole on cholesterol precursors and low density lipoprotein kinetics in hypercholesterolemia. J Lipid Res 1993; 34: 59-67.
24. Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, Huang SM. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 2009; 49: 351-9.
25. Björkhem-Bergman L, Bäckström T, Nylén H, Rönquist-Nii Y, Bredberg E, Andersson TB, Bertilsson L, Diczfalusy U. Comparison of endogenous 4-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. Drug Metab Dispos 2013; 41: 1488-93.
26. Shin KH, Choi MH, Lim KS. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clin Pharmacol Ther 2013; 94: 601-9.
27. Boulton DW, Arnaud P, DeVane CL. A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio. Br J Clin Pharmacol 2001; 51: 350-4.
28. Mårde Arrhén Y, Nylén H, Lövgren-Sandblom A, Kanebratt KP, Wide K, Diczfalusy U. A comparison of 4-hydroxycholesterol/cholesterol and 6-hydroxycortisol/cortisol as markers of CYP3A4 induction. Br J Clin Pharmacol 2013; 75: 1536-40.